Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Expert consensus on carotid stenting

This article was originally published in The Gray Sheet

Executive Summary

Stenting the carotid arteries is "a reasonable alternative" to gold-standard carotid endarterectomy in patients at high risk for surgery, according to a clinical expert consensus document published in the Jan. 2/9 Journal of the American College of Cardiology. However, there is insufficient evidence to support carotid stenting in high-risk patients with "asymptomatic stenosis less than 80% or in any patient without high-risk features." CMS likely will consider the consensus when it proposes a revised coverage decision for carotid stenting Feb. 2. Abbott/Guidant requested expanded coverage for all high-risk patients with symptomatic stenosis greater than 50% or asymptomatic stenosis greater than 80% (1"The Gray Sheet" Sept. 11, 2006, p. 6). Currently, Medicare covers symptomatic, high-risk patients with greater than 70% stenosis. Those patients with symptomatic stenosis between 50% and 70% or asymptomatic stenosis greater than 80% are covered only in FDA-approved studies. The consensus document was produced by five professional societies...

You may also be interested in...



Carotid Stent Firms See Another Step Into Market With Expanded Coverage

Carotid artery stent manufacturers hope to maintain momentum in an evolving market in which they see significant potential for growth

New EU Filings

Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.

BMS Has A Strong Pipeline, But Access Challenges Remain

Bristol Myers Squibb’s head of major markets, Monica Shaw, wants to improve patients’ access to lifesaving therapies. And the group has several new products ready to roll.

Latest Headlines
See All
UsernamePublicRestriction

Register

MT024360

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel